Previous Article | Next Article 
Journal of Virology, October 2001, p. 9780-9789, Vol. 75, No. 20
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.20.9780-9789.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Direct Activation of Innate and Antigen-Presenting
Functions of Microglia following Infection with Theiler's
Virus
Julie K.
Olson,
Ann M.
Girvin, and
Stephen D.
Miller*
Department of Microbiology-Immunology and
Interdepartmental Immunobiology Center, Northwestern University Medical
School, Chicago, Ilinois 60611
Received 18 May 2001/Accepted 23 July 2001
 |
ABSTRACT |
Microglia are resident central nervous system (CNS) macrophages.
Theiler's murine encephalomyelitis virus (TMEV) infection of SJL/J
mice causes persistent infection of CNS microglia, leading to the
development of a chronic-progressive CD4+ T-cell-mediated
autoimmune demyelinating disease. We asked if TMEV infection of
microglia activates their innate immune functions and/or activates
their ability to serve as antigen-presenting cells for activation of
T-cell responses to virus and endogenous myelin epitopes. The results
indicate that microglia lines can be persistently infected with TMEV
and that infection significantly upregulates the expression of
cytokines involved in innate immunity (tumor necrosis factor alpha,
interleukin-6 [IL-6], IL-18, and, most importantly, type I
interferons) along with upregulation of major histocompatibility
complex class II, IL-12, and various costimulatory molecules (B7-1,
B7-2, CD40, and ICAM-1). Most significantly, TMEV-infected microglia
were able to efficiently process and present both endogenous virus
epitopes and exogenous myelin epitopes to inflammatory CD4+
Th1 cells. Thus, TMEV infection of microglia activates these cells to
initiate an innate immune response which may lead to the activation of
naive and memory virus- and myelin-specific adaptive immune responses
within the CNS.
 |
INTRODUCTION |
Microglia are bone marrow-derived,
macrophage-like cells which populate the central nervous system (CNS).
These cells perform both scavenger (phagocytic) functions and
antigen-presenting cell (APC) functions (18, 32, 36, 51,
59). Microglia are activated early in response to infection or
injury and are major players in both innate and immune-mediated CNS
inflammatory responses (32, 58, 59). Multiple sclerosis
(MS) is an immune-mediated inflammatory disease in humans that is
characterized by peripheral T-cell responses to myelin proteins such as
myelin basic protein, proteolipid protein (PLP), and myelin
oligodendrocyte glycoprotein (MOG) (4, 14, 50, 67) and
demyelinating lesions in the brain and spinal cord associated with the
presence of both CD4+ T cells and activated
microglia-macrophages (35, 62). Epidemiological evidence
suggests that infection with a neurotropic virus may trigger the
development of MS (33).
Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating
disease (TMEV-IDD) serves as a highly relevant virus-induced model for
human MS (44). Infection of SJL/J mice with TMEV results in a life-long persistent infection of CNS microglia, macrophages, and
astrocytes (9, 39, 40). A chronic progressive autoimmune demyelinating disease is observed, with onset of clinical signs beginning around 30 to 35 days postinfection (37).
Clinical signs of ascending hind limb paralysis reflect the CNS
parenchymal and perivascular mononuclear cell infiltration and
demyelination (11, 13, 37). However, the chronic
progressive stage of the disease is mediated largely by
CD4+ myelin epitope-specific T cells activated via epitope
spreading (47).
Microglia originate from bone marrow precursors and then migrate into
the CNS during development and are considered to be a resident
macrophage population based on their expression of F4/80, FcR, and
Mac-1 (3, 18, 32, 36, 51, 59). The antigen-presenting
ability of microglia is somewhat controversial. In MS, microglia have
been shown to phagocytize myelin and express major histocompatibility
complex (MHC) class II along with costimulatory molecules, thus
indicating their potential to activate autoreactive CD4+
Th1 cells (1). In vitro studies have shown that microglia isolated from newborn rodents and humans are capable of functioning as
APCs following activation with proinflammatory cytokines such as gamma
interferon (IFN-
) (1). However, microglia tested directly upon isolation from adult mouse brains exist in a quiescent state compared to splenic macrophages (6). Collectively,
these studies indicate that activated microglia can perform APC
functions, but the extent of their participation in the initiation and
progression of CNS inflammatory diseases remains to be determined.
Previous studies addressing the consequences of virus infection of
CNS-resident cells utilized microglial cell lines or whole brain
macrophage populations and examined the expression of only a limited
number of activation markers. Infection of a human microglial cell line
with coronavirus showed increased nitric oxide (NO) production
(17). Infection of a glial cell line with measles virus
led to increased expression of MHC class I (15). A more recent study demonstrated the activation of a microglia-macrophage population in the brains of rats infected with bornavirus
(66). Relevant to TMEV-induced demyelinating disease,
previous studies have demonstrated that microglia-macrophages are the
predominant persistently infected cells in the CNSs of susceptible mice
(40) and that mouse brain macrophages can be infected with
TMEV in vitro (31, 34). Collectively, these previous
studies were unable to differentiate the effects of virus infection of
resident microglia from those of CNS-infiltrating macrophages and, more importantly, failed to address the effects of virus infection on APCs
and the effector function of these cells.
In the current study, we asked if TMEV infection of microglia activates
their innate immune functions and/or their ability to serve as APCs for
the activation of T-cell responses to virus and myelin epitopes.
Microglia isolated from the brains of SJL/J mice could be persistently
infected with TMEV in vitro, resulting in the upregulation of cytokines
involved in the innate immune response (tumor necrosis factor alpha
[TNF-
], interleukin-6 [IL-6], IL-12 IL-18, and, most
importantly, type I IFNs) along with a dramatic upregulation of IL-12
mRNA and surface expression of MHC class II and costimulatory molecules
(B7-1, B7-2, and CD40). Microglia activated by TMEV infection were able
to process and present both virus and myelin antigens to
CD4+ Th1 lines as efficiently as microglia treated with
IFN-
. Therefore, microglia respond to direct TMEV infection by
upregulating cytokines critical in the innate immune response and are
also capable of stimulating adaptive immune responses to virus and self
myelin proteins. This is the first report demonstrating that virus
infection of a quiescent APC population can directly lead to activation of APC function.
 |
MATERIALS AND METHODS |
Mice.
Pregnant (15 to 17 days) SJL/J mice were purchased
from Harlan Labs (Bethesda, Md.). Mice were housed in the Northwestern University animal facility in accordance with university and National Institutes of Health animal care guidelines. Neonatal mice 1 to 3 days
old were used for the isolation of microglia.
Antigens.
PLP139-151 (HSLGKWLGHPDKF),
PLP56-70 (DYEYLINVIHAFQYV),
PLP178-191 (NTWTTCQSIAFPSK),
VP270-86 (WTTSQEAFSHIRIPLPH), and
VP324-37 (PIYGKTISTPSDY) were purchased from
Peptides International (Louisville, Ky). The amino acid composition was verified by mass spectrometry, and purity was assessed by
high-performance liquid chromatography. Intact bovine PLP was prepared
from chloroform-methanol (2:1) extracts of bovine white matter as
previously described (23).
Media.
Mixed glial cultures were maintained in Dulbecco
modified Eagle medium (DMEM)-F12 (Sigma, St. Louis, Mo.) supplemented
with 10% fetal calf serum (FCS; Sigma), 6 g of glucose per liter,
2.4 g of NaHCO3 per liter, 0.37 g of
L-glutamine (Life Technologies, Gaithersburg, Md.) per
liter, 100 U of penicillin per ml, and 100 µg of streptomycin (Life
Technologies) per ml. Microglial cells were cultured in DMEM (Sigma)
supplemented with 20% FCS, 2 mM L-glutamine, and 3 ng
of recombinant murine granulocyte-macrophage colony-stimulating
factor (R&D Systems, Minneapolis, Minn.) per ml. T cells were
maintained in DMEM supplemented with 10% FCS, 2 mM
L-glutamine, 100 U of penicillin per ml, 100 µg of
streptomycin per ml, 50 µM 2-mercaptoethanol, 0.1 mM nonessential
amino acids, 1 mM sodium pyruvate (Life Technologies), minimum
essential medium essential vitamins (Life Technologies), 0.1 mM
asparagine (Life Technologies), 0.1 mg of folic acid (Life
Technologies) per ml, 0.8% T-STIM (Collaborative Biomedical Research,
Bedford, Mass.), and 0.2 U of recombinant IL-2 (Roche Molecular
Biochemicals, Indianapolis, Ind.) per ml. TMEV infection was conducted
in DMEM with no supplements. Proliferation assays and T-cell
stimulations were conducted in DMEM supplemented with 10% FCS, 5 mM
L-glutamine, 0.1 mM nonessential amino acids, 100 U of
penicillin per ml, 100 µg of streptomycin per ml, and 50 µM
2-mercaptoethanol.
Isolation and culture of microglia.
Isolation of mixed glial
cultures from neonatal mice was performed as previously described
(24, 60, 65). Briefly, tissue culture flasks were coated
for 3 h with 10 µg of poly-D-lysine (Sigma) per ml.
The brains were removed from 1- to 3-day-old neonatal mice, and the
meninges were removed. The left and right hemispheres of the brain were
gently dissociated in a nylon mesh bag. The resulting cell suspension
was passed through no. 60 and 100 stainless steel screens (Sigma). The
cells were centrifuged, and the cell pellet was resuspended in DMEM-F12
complete medium. The cells were seeded in the
poly-D-lysine-coated tissue culture flasks and incubated at
37°C. The medium was replaced at 3-day intervals. Following 10 to 14 days of incubation, microglia were removed from the astroglial layer by
shaking of the flasks on an orbital shaker for 24 h at 300 rpm.
The microglia which were shaken off into the medium were removed from
the flasks and centrifuged. The microglia were resuspended in DMEM
complete microglial medium and seeded in 24-well tissue culture plates
coated with poly-D-lysine. The microglia were cloned by
limiting dilution in DMEM complete microglia medium for 4 weeks to
obtain pure microglial cultures. Microglial cultures were maintained
for several months in 24-well tissue culture plates.
Virus infection.
The BeAn strain of TMEV was prepared and
purified from confluent BHK-21 cells infected with the BeAn 8386 strain
as previously described (38). Microglial cultures were
infected with strain BeAn at a multiplicity of infection of 5. The
microglia were washed twice with DMEM and then infected with the virus
in DMEM. The infected cultures were incubated at 20°C for 1 h
with intermittent shaking. Additional medium was added, and the
microglia were incubated for 48 h at 34°C.
Cell surface staining.
Microglia cultured in 24-well tissue
culture plates were incubated in the presence or absence of recombinant
IFN-
(100 U/ml) for 24 h at 37°C or infected with the BeAn
virus for 48 h. The cells were washed twice with cold
fluorescence-activated cell sorter (FACS) buffer
(phosphate-buffered saline [PBS] with 5% normal goat serum).
Microglia were incubated with normal mouse serum and Fc receptor block
for 30 min at 4°C. The microglia were then incubated for 45 min at
4°C with antibodies directly conjugated to biotin for the antigens
Mac-1 (CD11b), CD45, CD40, ICAM-1 (CD54), B7-1 (CD80), B7-2 (CD86),
H-2Ks (MHC class I), and I-As (MHC class II) or
the appropriate isotype control antibody controls (PharMingen).
Following the antibody binding, the microglia were washed twice with
FACS buffer and then incubated with streptavidin-fluorescein isothiocyanate for 30 min at 4°C. Microglia were washed twice before
gentle removal of the cells from the surface. The stained cells were
analyzed on a Becton Dickinson FACS Calibur. The flow plots shown
represent all of the cells derived from each of the various culture
conditions, with 5 to 8% of the events consisting of cellular debris
based on forward versus side scatter analysis.
RNA isolation and reverse transcription (RT)-PCR cytokine
analysis.
Microglia were incubated in the presence or absence of
recombinant IFN-
, for 24 h, or infected with strain BeAn for
48 h for time periods predetermined to be optimal for gene
expression under each condition. The cells were washed twice with PBS
and then gently scraped from the surface of the tissue culture plate. The microglia were counted and pelleted, and total RNA was isolated from the cells by using an SV Total RNA Isolation Kit (Promega, Madison, Wis.). First-strand cDNA was generated from 1 µg of total RNA from the microglia by using oligo(dT)12-18 primers and an Advantage for RT for PCR Kit (Clontech Laboratories, Palo Alto, Calif.). Following synthesis, each cDNA sample was diluted in distilled
water to a 100-µl volume and 10 µl was used for each PCR. Each PCR
was conducted in a 50-µl volume containing 50 mM KCl, 10 mM Tris-Cl
(pH 8.3), 5 mM MgCl2, 2 mM deoxynucleoside triphosphates,
100 pmol of each 5' and 3' gene-specific primer, 1 U of Taq
polymerase (Qiagen, Chatsworth, Calif.), and 10 µl of diluted cDNA.
The primers were synthesized by Life Technologies. PCR cycle conditions
were 30 cycles of 94°C for 40 s, 60°C for 20 s, and
72°C for 40 s, followed by a final extension at 72°C for 5 min. PCR products were separated on an ethidium bromide-containing 2%
agarose gel, illuminated on a UV light source, and photographed using
Polaroid type 667 film. Gel images were scanned into Adobe Photoshop
using an Epson ES 1200-C scanner and imported as TIFF files into Kodak
1D Digital Science for densitometry. The sequences of the cytokine
primers and the expected product sizes are as follows: IFN-
, 5'
primer 5' GAC TCA TCT GCT GCT TGG AAT GCA ACC CTC C 3' and
3' primer 5' GAC TCA CTC CTT CTC CTC ACT CAG TCT TGC C 3'
(294 bp); IFN-
, 5' primer 5' CAG CTC CAG CTC CAA GAA AGG
ACG AAC ATT CG 3' and 3' primer 5' CCA CCA CTC ATT CTG AGG CAT CAA CTG ACA GG 3' (509 bp); IL-1
, 5' primer 5' AAG
CTC TCC ACC TCA ATG GAC AG 3' and 3' primer 5' CTC AAA CTC
CAC TTT GCT CTT GA 3' (260 bp); IL-6, 5' primer 5' CCT CTG
GTC TTC TGG AGT ACC AT 3' and 3' primer 5' GGC ATA ACG CAC
TAG GTT TGC CG 3' (307 bp); IL-10, 5' primer 5' CCA GTT TTA
CCT GGT AGA AGT GAT G 3' and 3' primer 5' TGT CTA GGT CCT
GGA GTC CAG CAG ACT CAA 3' (324 bp); IL-12 p40, 5' primer 5'
ATG GCC ATG TGG GAG CTG GAG AAA G 3' and 3' 5' GTG GAG CAG
CAG ATG TGA GTG GCT 3' (451 bp); IL-18, 5' primer 5' CTG TGT
TCG AGG ATA TGA CTG 3' and 3' primer 5' GTG TCC TTC ATA CAG
TGA AG 3' (283 bp); TNF-
, 5' primer 5' GTT CTA TGG CCC
AGA CCC TCA CA 3' and 3' primer 5' TAC CAG GGT TTG AGC TCA
GC 3' (364 bp); inducible no synthase (iNOS), 5' primer 5' TGG GAA TGG AGA CTG TCC CAG 3' and 3' primer 5' GGG ATC TGA
ATG TGA TGT TTG 3' (306 bp); MIP-1
, 5' primer 5' ATG AAG
GTC TCC ACC ACT GCC CTT G 3' and 3' primer 5' GGC ATT CAG
TCC AGG TCA GTG AT 3' (276 bp); IFN-
, 5' primer 5' CTT
GGA TAT CTG GAG GAA CTG GC 3' and 3' primer 5' GCG CTG GAC
CTG TGG GTT GTT GA 3' (271 bp); hypoxanthine
phosphoribosyltransferase (HPRT), 5' primer 5' GTT GGA TAC AGG CCA
GAC TTT GTT G 3' and 3' primer 5' GAG GGT AGG CTG GCC TAT
AGG CT 3' (352 bp).
T-cell proliferation assays and cytokine assays.
CD4+ Th1 T-cell lines specific for TMEV
VP270-86 and VP324-37 and for
PLP56-70, PLP139-151, and
PLP178-191, were derived from lymph nodes removed from
SJL/J mice 10 days after priming with a complete Freund's
adjuvant emulsion containing 50 µg of the respective peptide
and 200 µg of Mycobacterium tuberculosis H37Ra (Difco
Laboratories, Detroit, Mich.). The T cells were stimulated in vitro
every 3 to 4 weeks with 5 × 106 irradiated syngeneic
spleen cells and the respective peptide at 25 µM for every
106 T cells. The T cells were maintained between
stimulations in the appropriate medium and used for the T-cell
proliferations 14 to 21 days after stimulation. For the T-cell
proliferation assays, microglia were cultured in 96-well tissue culture
plates (2 × 105 cells per well) and either infected
with TMEV for 48 h or stimulated with IFN-
for 24 h. The
microglia were washed twice with medium, irradiated, and cultured with
5 × 104 T cells and the appropriate peptide at 10 to
50 µM. The cells were pulsed at 72 h with 1 µCi of
[3H]thymidine and then harvested and counted at 96 h. Proliferation was determined with triplicate wells for each
condition and then expressed as mean counts per minute ± the
standard error of the mean (SEM). Stimulation indices (SI) were
determined by dividing the counts per minute in cultures with added
antigen by the counts per minute in wells containing PBS. For cytokine
analysis, a duplicate set of proliferation wells was used to collect
supernatants at 48 and 72 h. The concentrations of IFN-
and
TNF-
were quantitated with indirect enzyme-linked immunosorbent
assays (Endogen Inc., Woburn, Mass.) with detection limits of ~100
pg/ml for IFN-
and ~50 pg/ml for TNF-
.
 |
RESULTS |
Isolation and characterization of microglia from SJL/J mouse
brains.
Microglial cells were isolated from the brains of newborn
SJL/J mice. Flow cytometry was used to analyze the isolated microglia for the expression of cell surface markers (Fig.
1). These cells failed to express GFAP,
B220, or CD11c markers for astrocytes, B cells, and dendritic cells,
respectively, indicating lack of contamination of the cultures with
blood-derived cells (data not shown). SJL microglia expressed Mac-1
(CD11b) and F4/80 on the cell surface (Fig. 1), similar to splenic
peripheral macrophages, but unlike peripheral APCs, they failed to
express MHC class II (data not shown). The distinguishing difference
between microglia and macrophage populations is the level of CD45
expression on the cell surface (19). Macrophages express
high levels of CD45, while microglia express low-to-moderate levels of
CD45. Similar to previous reports (6), the isolated
microglia population expressed an intermediate level of CD45
(19). The microglia also expressed low levels of B7-1 and
almost no B7-2 and ICAM-1 and did not express MHC class I, MHC class
II, or CD40. As previous studies have shown that IFN-
activates
microglia (2, 20), we assessed the effects of IFN-
activation on cell surface antigen expression. IFN-
-stimulated
microglia expressed slightly higher levels of Mac-1 and CD45 than did
unstimulated microglia (Fig. 1). However, IFN-
-stimulated microglia
significantly upregulated cell surface expression of the APC-related
B7-1, B7-2, ICAM-1, CD40, MHC class I, and MHC class II molecules.

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 1.
Expression of APC surface markers on unstimulated and
IFN- -treated SJL microglia. Microglia cultures were unstimulated or
stimulated with IFN- for 24 h. The microglia were stained with
antibodies for Mac-1 (CD11b), CD45, ICAM-1 (CD54), CD40, B7-1 (CD80),
B7-2 (CD86), MHC class II (I-AS), and MHC class I
(H-2KS). Surface expression was then analyzed by flow
cytometry, with the single line in each histogram representing the
isotype antibody control and the solid peak representing the surface
marker staining listed on the x axis. The flow plots shown
represent all of the cells derived from each of the various culture
conditions. These results are representative of four separate
experiments.
|
|
Viral infection stimulates microglial APC surface marker
expression.
Microglia have previously been suggested to be a major
source of persistent virus in the CNS during TMEV infection (9, 40). In addition, brain macrophages can be infected in vitro with the DA strain of TMEV and produce detectable levels of viral RNA
and release viral particles (34). We thus asked if TMEV infection of SJL microglia would result in a persistent infection and,
if so, what effect the infection would have on the activation state of
these cells. SJL microglia were infected for 48 h and then
analyzed by flow cytometry for the presence of viral proteins using two
virus-specific antibodies. The infected microglia contained a high
level of viral proteins compared to microglia infected with
UV-inactivated BeAn (Fig. 2). In
addition, no significant loss in the number of microglia was detected
(data not shown), suggesting that the virus had no significant
cytolytic affect on the microglia compared to other cell types (e.g.,
BHK-21) which are lysed by the virus within 24 h following
infection. Thus, infection of microglia with TMEV resulted in
persistent infection of the cells, which could be maintained in culture
for 1 to 2 weeks with similar levels of viral proteins, as determined
by flow cytometric analysis (data not shown). TMEV-infected microglia were next analyzed to determine the effect of virus infection on the
expression of APC-related molecules (Fig.
3). TMEV-infected microglia upregulated
the cell surface expression of B7-1, B7-2, ICAM-1, CD40, MHC class I,
and MHC class II compared to microglia incubated with UV-inactivated
TMEV-uninfected microglia. With the exception of that of CD40,
expression levels of the various molecules in virus-infected microglia
were similar to the levels induced by stimulation with IFN-
(Fig.
1). Thus, TMEV infection, similar to activation with IFN-
, leads to
microglial activation and expression of MHC and costimulatory molecules
required for antigen presentation to CD4+ T cells.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 2.
SJL mouse microglia can be persistently infected with
viable TMEV. Microglia were infected for 48 h with either viable
or UV-inactivated strain BeAn of TMEV and then stained with an anti-VP3
monoclonal antibody (mAb) or polyclonal antiserum raised against TMEV
(supplied by Robert Fujinami). The single line in each histogram
represents the isotype antibody control. The solid peak in each
histogram represents anti-TMEV staining.
|
|

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 3.
SJL microglia infected with TMEV upregulate expression
of APC surface markers. Microglia were infected for 48 h with the
BeAn strain of TMEV and then stained with antibodies for Mac-1, CD45,
ICAM-1, CD40, B7-1, B7-2, MHC class II, and MHC class I. The single
line in each histogram represents the isotype antibody control. The
solid peak in each histogram represents the specific antibody staining
for the surface markers listed on the x axis. These results
are representative of four separate experiments.
|
|
TMEV-infected microglia express cytokines involved in both innate
and adaptive immune responses.
IFN-
and TMEV-infected microglia
were next compared for the ability to express critical cytokines and
chemokines, which may direct the migration and activation of CNS
inflammatory cells. Recent reports have shown that multiple cytokines
are secreted during the innate immune response to infectious agents,
and these cytokines not only direct the innate immune response but also determine the nature of the ensuing adaptive immune response
(42). TMEV is a picornavirus and thus contains a
positive-sense RNA genome. It is well established that double-stranded
RNA can act as a "molecular pattern" recognized by "pattern
recognition molecules" of the innate immune system (25).
Activation of these molecules by double-stranded RNA results in
cytokine expression, most importantly type I IFNs, IFN-
and IFN-
.
Therefore, expression of multiple chemokines, cytokines, and
inflammatory effector molecules was analyzed by RT-PCR methods. mRNA
was isolated from microglia cultured with no additions, cultured with
IFN-
, or infected with viable or UV-inactivated TMEV (Fig.
4). The levels of expression were normalized to the expression of the housekeeping gene for HPRT. Unstimulated microglia expressed low levels of IL-1
, IL-6, IL-18, TNF-
, iNOS, and MIP1-
and failed to express IL-10 or IL-12 p40. Microglia stimulated with IFN-
upregulated the expression of IL-1
, IL-6, IL-18, TNF-
, iNOS, and MIP1-
mRNAs.
IFN-
-stimulated microglia also expressed low levels of IFN-
and
IL-10 and a moderate level of IL-12 p40 mRNA. Interestingly, microglia
infected with viable, but not with UV-inactivated, TMEV also
upregulated the expression of high levels of IFN-
, IFN-
, IL-1
,
IL-6, IL-18, TNF-
, iNOS, and MIP1-
mRNAs and low-to-moderate
levels of IL-10 and IL-12 p40. As expected, neither unstimulated nor
stimulated microglia expressed detectable levels of the IFN-
message. The light bands in the IFN-
gel lanes (Fig. 4) are
nonspecific bands and do not correspond to the 271-bp size expected for
IFN-
. Therefore, TMEV infection of microglia resulted in upregulated
expression of multiple cytokines critical for initiating and
controlling the innate immune response, as well as in triggering of the
adaptive immune response. Persistently infected microglia also
expressed a relevant chemokine (MIP-1
) involved in T-cell
trafficking to the CNS and inflammatory effector molecules (IL-1
,
IL-6, TNF-
, and iNOS) which are important in the innate and adaptive
immune responses in the CNS.

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 4.
Induction of cytokine and chemokine mRNA expression by
IFN- -treated and TMEV-infected SJL mouse microglia. RNA were
isolated from unstimulated microglia, from microglia stimulated with
IFN- for 24 h, and from microglia infected with viable or UV
inactivated TMEV 48 h previously for time periods determined in
preliminary experiments to be optimal for gene expression. The RNA for
each microglia group was then analyzed by RT-PCR to determine IFN- ,
IFN- , IL-1 , IL-6, IL-10, IL-12, IL-18, TNF- , iNOS, MIP-1 ,
IFN- , and HPRT mRNA expression levels. The products were separated
on a 2% agarose gel and then analyzed for expression of the various
cytokines relative to the HPRT expression levels (A). Similar results
were observed in 10 separate experiments. (B) The mRNA levels for the
various molecules are presented as percentages of the expression of
HPRT based on densitometric scanning.
|
|
Virus-infected microglia can process and present myelin protein
epitopes.
During acute TMEV infection of SJL mice,
macrophage-microglia-mediated bystander damage to myelin results in the
phagocytosis and processing of myelin debris by these mononuclear cells
(31). Previous reports from our laboratory have shown that
CD45+ APCs isolated from the CNSs of TMEV-infected mice
present various myelin basic protein, PLP, and MOG peptides during the
ongoing demyelinating disease (31, 52). As a result,
epitope spreading is initiated wherein CD4+ T-cell
responses to the immunodominant PLP139-151 epitope are
initiated approximately 3 weeks after the onset of clinical disease and
responses to additional myelin epitopes (MOG92-106, PLP56-70, and PLP178-191) develop as the
disease progresses (47). Thus, microglia, particularly
those infected with TMEV or activated by IFN-
, may play a critical
role in the processing and presentation of myelin epitopes to
CNS-infiltrating CD4+ T cells during chronic autoimmune
demyelinating diseases. The current results indicate that TMEV-infected
microglia upregulate MHC class II and costimulatory molecules (B7-1,
B7-2, and CD40). We thus compared the abilities of unstimulated and
stimulated microglia to process and present myelin protein epitopes to
specific Th1 cells.
The microglia were analyzed by using T-cell proliferation assays to
determine their ability to present PLP peptides to specific CD4+ T-cell lines. Unstimulated microglia were unable to
effectively present PLP139-151 (Fig.
5A), PLP178-191 (Fig. 5B), or PLP56-70 (Fig. 5C) to induce proliferation of specific Th1 lines. However, microglia stimulated with IFN-
induced
significant activation of T-cell lines specific for each of these
epitopes. TMEV-infected microglia also effectively presented these
epitopes in comparison to control cells infected with UV-inactivated
TMEV. It should be stressed that professional APCs (i.e., splenic
macrophages) were more efficient in presenting PLP peptides than either
IFN-
-stimulated or TMEV-infected microglia with SI two- to threefold
higher than the SI of microglia (data not shown). The microglia were
further analyzed for the ability to process PLP139-151
from intact PLP and present the peptide to
PLP139-151-specific T cells. IFN-
-stimulated and
TMEV-infected microglia were able to process and present
PLP139-151 from intact PLP to PLP139-151 CD4+ T cells, while unstimulated and UV-inactivated
TMEV-infected microglia were ineffective (Fig. 5D). Similar results
were obtained when microglia were analyzed for the ability to process
and present PLP178-191 and PLP56-70 peptides
from intact PLP (data not shown). Therefore, TMEV infection of
microglia conferred an antigen-presenting function on these cells,
indicating their potential importance in presenting endogenous myelin
peptides during chronic demyelinating diseases.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 5.
Activated microglia process and present myelin epitopes
to initiate proliferation in CD4+ Th1 lines. Microglia were
unstimulated, stimulated for 24 h with IFN- , or infected for
48 h with viable or UV-inactivated TMEV. The cells were cultured
with various concentrations of PLP139-151 (A),
PLP178-191 (B), or PLP56-70 (C) and the
corresponding specific T-cell lines for 96 h. Alternatively,
microglia were cultured with whole PLP protein and
PLP139-151-specific T cells (D). T-cell proliferation was
determined by [3H]thymidine incorporation during the last
24 h of the assay. Proliferation is expressed as mean
counts per minute ± the SEM, and the SI is listed above each bar.
These results are representative of five separate experiments.
|
|
The abilities of the various microglial populations to activate
proinflammatory cytokine (IFN-
and TNF-
) production by the PLP
peptide-specific Th1 lines were also assessed. Interestingly, PLP178-191-pulsed, unstimulated microglia induced the
secretion of moderate levels of both IFN-
(Fig.
6A) and TNF-
(Fig. 6B) from the
PLP178-191-specific T-cell line, despite the fact that the
Th1 cells in these cultures failed to proliferate (Fig. 5B). IFN-
secretion was observed in T cells cocultured with unstimulated, IFN-
-stimulated, and TMEV-infected microglia (Fig. 6A), despite the
differential abilities of these microglial populations to induce
proliferation, indicating that IFN-
secretion is independent of
T-cell proliferation. In contrast, although unstimulated microglia also
induced the production of moderate amounts of TNF-
, its production
was higher when the T-cell lines were activated with IFN-
-stimulated
microglia or microglia infected with viable TMEV (Fig. 6B). Similar
proinflammatory cytokine expression patterns were also observed when
T-cell lines specific for PLP139-151 and
PLP56-70 were used (data not shown). Consistent with their
failure to induce proliferation, unstimulated microglia and those
infected with UV-inactivated TMEV failed to induce IL-2 production from
the myelin-specific Th1 lines (data not shown). Collectively, these
results indicate that both naive and activated microglia can support
the production of proinflammatory cytokines from myelin-specific Th1
cells.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 6.
Both resting and activated microglia induce
proinflammatory cytokine secretion from
PLP178-191-specific Th1 cells. Culture supernatants were
collected at 48 h from the PLP178-191-specific T-cell
proliferation assay (Fig. 5B). The supernatants were analyzed by
enzyme-linked immunosorbent assays for IFN- (A) and TNF- (B).
Secretion of each cytokine was determined for the differing peptide
concentrations listed and expressed as nanograms per milliliter. The
values above the bars indicate the fold increases in cytokine
expression over that of the PBS control (1.0). These experiments were
performed five times, and the results of one representative
experiment are shown.
|
|
Microglia infected with strain BeAn can process and present
endogenous viral antigens.
Since TMEV establishes a persistent
infection of microglia in the CNS, it was of interest to determine if
microglia persistently infected with TMEV could process and present
viral antigens from the infecting virus. Thus, microglia were infected
with the strain BeAn virus or the UV-inactivated strain BeAn virus and
then cultured with T cells specific for the immunodominant viral
protein epitopes VP270-86 (21) and
VP324-37 (69) in an antigen presentation
assay (Fig. 7). As anticipated,
activation of the VP2- and VP3-specific T cells was significantly
enhanced when the peptide was presented by IFN-
-stimulated microglia
rather than by unstimulated cells. Most interestingly, TMEV-infected microglia activated the proliferation of both lines in the absence of
added peptide while UV-inactivated TMEV-infected microglia did not
activate the proliferation of these virus-specific T-cell lines.
Therefore, TMEV-infected microglia can process and present viral
epitopes from the infecting virus to CD4+ T cells,
indicating that the virus peptides can access the MHC class II
processing-presentation pathway. This was confirmed by showing that
proliferation of the VP2- and VP3-specific T-cell lines could be
inhibited by the addition of anti-I-As monoclonal antibody
MK-S4 to the culture (data not shown).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 7.
Virus-infected microglia process and present endogenous
viral antigens to CD4+ T cells. Microglia were
unstimulated, stimulated for 24 h with IFN- , or infected for 48 h with viable TMEV or UV-inactivated TMEV, irradiated, and incubated
with T cells specific for immunodominant TMEV capsid protein epitope
VP270-86 or VP324-37 for 96 h in the
presence or absence of the specific VP peptide. T-cell proliferation
was determined by [3H]thymidine incorporation during the
last 24 h of the assay. Viral peptides were not added to the
virus-infected microglia (ND). Proliferation is expressed as the mean
change in counts per minute ± the SEM, where the
background of wells containing PBS for each group was subtracted from
the experimental wells, and the SI is listed above each bar. These data
are representative of three separate experiments.
|
|
 |
DISCUSSION |
The results reported here show that microglia from SJL/J mice can
be persistently infected in vitro with TMEV and that, as a result of
this infection, these cells are activated to function as competent APCs
with the ability to process and present both virus and myelin epitopes
to memory CD4+ Th1 cells. Concomitant with the acquisition
of this functional antigen presentation capacity, TMEV infection
induced the upregulation of cytokines involved in innate immune
responses and of cytokines and costimulatory molecules required for the
activation and differentiation Th1 effector cells. Most significantly,
direct TMEV infection of microglia was nearly as effective as
stimulation with high levels of IFN-
in conferring APC function.
TMEV-IDD is a well-characterized CD4+ T-cell-mediated model
of MS (44). Life-long persistent viral infection of
CNS-resident microglia, macrophages, and astrocytes (9, 39,
40) is directly related to the development of the chronic
demyelinating disease (8). Initial myelin damage is
mediated by a bystander mechanism wherein the primary effector cells
are mononuclear phagocytes (microglia-macrophages) activated by
inflammatory cytokines produced from TMEV-specific Th1 cells responding
to viral epitopes that persist in the CNS (29, 45, 46).
Early myelin destruction leads to the de novo activation of
myelin-specific T cells. The initial myelin response is directed toward
the immunodominant PLP139-151 epitope (47),
and epitope spreading then leads to an ordered progression of T-cell
responses to multiple myelin autoepitopes which appear to play a
significant role in the chronic phase of the disease by escalating the
demyelinating process (31).
TMEV infection of microglia led to the rapid upregulation of mRNA for
multiple cytokines involved in mediating both innate and adaptive
immune responses (Fig. 3). Cytokines produced by the innate immune
response have a critical role in shaping the ensuing adaptive immune
responses, as well as other innate immune responses (42).
The innate immune response recognizes invading pathogens by
differentiating self from non-self by using pattern recognition
receptors which recognize pathogen-expressed molecular arrays or
patterns (43). Much attention has recently focused on the
initiation of innate immune responses to bacterial infections through
the mammalian Toll-like receptors, but it has long been recognized that
type I interferons, IFN-
and IFN-
, are produced in response to
double-stranded RNA (25). Double-stranded RNA is commonly
found in the replication cycles of multiple viruses, including TMEV,
but is not found in mammalian cells (42). Type I
interferons are best known for preventing viral infection, but IFN-
and IFN-
also elicit the secretion of IFN-
by natural killer
cells and T cells, which promotes Th1 responses (10).
Via the production of cytokines and chemokines, the innate immune
response can signal the development of an inflammatory response, can
function in activating various Th subsets through the upregulation of
MHC molecule expression and regulation of costimulatory molecules, and
can control the induction of inflammatory effector functions (42). TMEV-infected microglia induced new expression of
IFN-
, IFN-
, IL-10, and IL-12 and significantly upregulated the
basal expression of IL-1
, IL-6, IL-18, TNF-
, iNOS, and MIP-1
(Fig. 4). Expression of type 1 interferons, IFN-
and IFN-
,
induced by double-stranded RNA, can regulate the innate response
through transcriptional control of the expression of several cytokines and APC surface markers. Viral RNA can induce the expression of cytokines-chemokines such as IL-1
, TNF-
, IL-6, and MIP1-
,
which direct the inflammatory response by controlling the migration of
T cells to the site of infection (28, 49, 54, 57, 64).
TMEV infection of microglia also resulted in upregulation of the
expression of TNF-
, IL-12, and IL-18, which contribute to the
activation and differentiation of proinflammatory Th1 T cells (5,
27). In addition, TMEV-infected microglia upregulated the
expression of MHC and costimulatory molecules necessary for Th1
expansion. The innate response has been shown to upregulate MHC class I
and class II on the surface of APCs through control of transcriptional
regulators (42, 56). Double-stranded RNA has also been
shown to induce the expression of the B7-1 and B7-2 costimulatory
molecules and of other costimulatory molecules (ICAM-1 and CD40) that
contribute to T-cell activation (22, 25).
TMEV infection of microglia also led to the upregulation of various
genes, e.g., that for TNF-
, whose products have been implicated in
the effector stages of the demyelination process (55).
Expression of iNOS results in the production of NO, which regulates the
production of various cytokines at the transcriptional and
posttranscriptional levels. Activation of microglia by IFN-
and
IFN-
-dependent processes following intracellular microbial infections and by CD40-CD40 ligand interactions can upregulate the
production of effector inflammatory mediators, e.g., NO and matrix
metalloproteinases (41, 61), which aggravate inflammatory processes (16, 53, 63). Thus, microglia-macrophages
activated directly by TMEV infection may also contribute to the
effector phase of myelin destruction (12).
It is of great interest to determine whether the autoreactive Th1 cells
induced via epitope spreading are activated locally in the CNS and/or
in the peripheral lymphoid organs and to determine which APC
populations (CNS resident and/or peripheral) present endogenous myelin
peptides. The CNS contains several cell types which may serve as
APCs
microglia, astrocytes, and cerebrovascular endothelial cells
(1, 48, 60, 68). In support of the possibility that
microglia, either activated directly by TMEV infection or via
Th1-derived IFN-
, may present endogenous myelin epitopes in
TMEV-infected mice, previous studies have determined that
microglia-macrophages in the CNSs of TMEV-infected SJL mice contain
infectious virus (9, 40) and ingested myelin debris (31). We have also shown that the majority of
F4/80+ macrophages-microglia isolated from the spinal cords
of mice with ongoing TMEV-induced demyelinating disease coexpress high levels of MHC class II as well as B7-1 and B7-2, and that these cells
endogenously present both virus and self myelin epitopes to specific
Th1 lines (30, 31, 52). However, these studies were unable
to differentiate microglia from CNS-infiltrating macrophages to
determine their individual roles in viral and myelin immune responses.
The present results demonstrate that viral infection of isolated
microglial cells can directly induce upregulation of MHC classes I and
II, necessary for T-cell receptor signaling, as well as a
variety of costimulatory molecules (B7-1, B7-2, CD40, and ICAM-1) (Fig.
3) required for the activation of both naive and memory Th1 cells
(26). Critically, the current results demonstrate that
TMEV-infected microglia were able to process and present endogenous
viral epitopes from the infecting virus (Fig. 7) and various PLP
epitopes (Fig. 5 and 6) to antigen-specific Th1 cells, indicating that
microglia may play a critical role both in the initiation of myelin
destruction via activation of TMEV-specific T cells and in epitope
spreading via activation of myelin epitope-specific T cells (30,
31). Our results also confirm an earlier report on microglia
isolated from normal adult brain (7) by showing that
unstimulated cells are unable to activate the proliferation of Th1
clones (Fig. 5) but are able to induce proinflammatory cytokine
production (Fig. 6) in spite of the minimal endogenous expression of
MHC class II and costimulatory molecules.
In summary, the current in vitro analysis demonstrates that persistent
infection of microglia with TMEV induces potent activation of the
innate immune response. The consequences of this activation have
important implications for the initial inflammatory response, the
ensuing adaptive immune response, and the effector mechanisms involved
in myelin destruction in TMEV-IDD. Early expression of proinflammatory
cytokines and chemokines in the CNSs of infected mice leads to the
initial infiltration of peripherally activated virus-specific
CD4+ T cells. Activated microglia which have upregulated
MHC class II and costimulatory molecules can then induce the further
activation of these T cells, triggering the production of Th1-derived
proinflammatory chemokines-cytokines, including IFN-
, which would
lead to the further influx and activation of peripheral
monocytes-macrophages. Activated microglia can then induce myelin
destruction via the secretion of effector molecules (e.g., TNF-
and
NO), resulting in the uptake, processing, and presentation of ingested
endogenous myelin epitopes. In turn, this would lead to the local
activation of myelin-specific autoreactive T cells, which play a major
role in chronic disease progression by perpetuating the chronic
inflammatory process (47). Collectively, our results
suggest that microglia may provide the first response to invading
viruses through an innate immune response and subsequently direct the
development of the adaptive immune response in the CNS initially to the
invading pathogen and subsequently to tissue-specific autoantigens.
 |
ACKNOWLEDGMENTS |
This work was supported in part by USPHS NIH grants NS23349,
NS40460, and NS30871. J.K.O. was supported by postdoctoral fellowships from the Spinal Cord Research Foundation (2046-01) and the NIH (F32
NS-10893). A.M.G. was supported by NIH training grant T32 AI-07476.
We thank Carol L. Vanderlugt for critical review of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology-Immunology, Northwestern University Medical School, 303 E. Chicago Ave., Chicago, IL 60611. Phone: (312) 503-7674. Fax: (312)
503-1154. E-mail: s-d-miller{at}nwu.edu.
 |
REFERENCES |
| 1.
|
Aloisi, F.,
F. Ria, and L. Adorini.
2000.
Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes.
Immunol. Today
21:141-147[CrossRef][Medline].
|
| 2.
|
Aloisi, F.,
F. Ria,
G. Penna, and L. Adorini.
1998.
Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 activation.
J. Immunol.
160:4671-4680[Abstract/Free Full Text].
|
| 3.
|
Barron, K. D.
1983.
Comparative observations on the cytological reactions of central and peripheral nerve cells to axotomy, p. 7-40.
In
C. C. Kao, R. P. Bunge, and P. J. Reier (ed.), Spinal cord reconstruction. Raven Press, New York, N.Y.
|
| 4.
|
Bernard, C. C., and N. K. de Rosbo.
1991.
Immunopathological recognition of autoantigens in multiple sclerosis.
Acta Neurol.
13:171-178[Medline].
|
| 5.
|
Biron, C. A.,
K. B. Nguyen,
G. C. Pien,
L. P. Cousens, and T. P. Salazar-Mather.
1999.
Natural killer cells in antiviral defense: function and regulation by innate cytokines.
Annu. Rev. Immunol.
17:189-220[CrossRef][Medline].
|
| 6.
|
Carson, M. J.,
C. R. Reilly,
J. G. Sutcliffe, and D. Lo.
1998.
Mature microglia resemble immature antigen-presenting cells.
Glia
22:72-85[CrossRef][Medline].
|
| 7.
|
Carson, M. J.,
J. G. Sutcliffe, and I. L. Campbell.
1999.
Microglia stimulate naive T-cell differentiation without stimulating T-cell proliferation.
J. Neurosci. Res.
55:127-134[CrossRef][Medline].
|
| 8.
|
Clatch, R. J.,
H. L. Lipton, and S. D. Miller.
1987.
Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. II. Survey of host immune responses and central nervous system virus titers in inbred mouse strains.
Microb. Pathog.
3:327-337[CrossRef][Medline].
|
| 9.
|
Clatch, R. J.,
S. D. Miller,
R. Metzner,
M. C. Dal Canto, and H. L. Lipton.
1990.
Monocytes/macrophages isolated from the mouse central nervous system contain infectious Theiler's murine encephalomyelitis virus (TMEV).
Virology
176:244-254[CrossRef][Medline].
|
| 10.
|
Cousens, L. P.,
R. Peterson,
S. Hsu,
A. Dorner,
J. D. Altman,
R. Ahmed, and C. A. Biron.
1999.
Two roads diverged: interferon alpha/beta and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection.
J. Exp. Med.
189:1315-1328[Abstract/Free Full Text].
|
| 11.
|
Dal Canto, M. C., and R. L. Barbano.
1985.
Immunocytochemical localization of MAG, MBP and P0 protein in acute and relapsing demyelinating lesions of Theiler's virus infection.
J. Neuroimmunol.
10:129-140[CrossRef][Medline].
|
| 12.
|
Dal Canto, M. C., and H. L. Lipton.
1975.
Primary demyelination in Theiler's virus infection. An ultrastructural study.
Lab. Investig.
33:626-637[Medline].
|
| 13.
|
Dal Canto, M. C., and H. L. Lipton.
1982.
Ultrastructural immunohistochemical localization of virus in acute and chronic demyelinating Theiler's virus infection.
Am. J. Pathol.
106:20-29[Abstract].
|
| 14.
|
de Rosbo, N. K.,
M. Hoffman,
I. Mendel,
I. Yust,
J. Kaye,
R. Bakimer,
S. Flechter,
O. Abramsky,
R. Milo,
A. Karni, and A. Ben-Nun.
1997.
Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions.
Eur. J. Immunol.
27:3059-3069[Medline].
|
| 15.
|
Dhib-Jalbut, S.,
J. Xia,
H. Rangaviggula,
Y. Y. Fang, and T. Lee.
1999.
Failure of measles virus to activate nuclear factor-kappa B in neuronal cells: implications on the immune response to viral infections in the central nervous system.
J. Immunol.
162:4024-4029[Abstract/Free Full Text].
|
| 16.
|
Diefenbach, A.,
H. Schindler,
N. Donhauser,
E. Lorenz,
T. Laskay,
J. MacMicking,
M. Rollinghoff,
I. Gresser, and C. Bogdan.
1998.
Type 1 interferon (IFNalpha/beta) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite.
Immunity
8:77-87[CrossRef][Medline].
|
| 17.
|
Edwards, J. A.,
F. Denis, and P. J. Talbot.
2000.
Activation of glial cells by human coronavirus OC43 infection.
J. Neuroimmunol.
108:73-81[CrossRef][Medline].
|
| 18.
|
Federoff, S.
1995.
Development of microglia, p. 162-181.
In
H. Kettenmann, and B. R. Ransom (ed.), Neuroglia. Oxford University Press, Oxford, England.
|
| 19.
|
Ford, A. L.,
A. L. Goodsall,
W. F. Hickey, and J. D. Sedgwick.
1995.
Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4+ T cells compared.
J. Immunol.
154:4309-4321[Abstract].
|
| 20.
|
Frei, K.,
C. Siepl,
P. Groscurth,
S. Bodmer,
C. Schwerdel, and A. Fontana.
1987.
Antigen presentation and tumor cytotoxicity by interferon-gamma-treated microglial cells.
Eur. J. Immunol.
17:1271-1278[Medline].
|
| 21.
|
Gerety, S. J.,
W. J. Karpus,
A. R. Cubbon,
R. G. Goswami,
M. K. Rundell,
J. D. Peterson, and S. D. Miller.
1994.
Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. V. Mapping of a dominant immunopathologic VP2 T cell epitope in susceptible SJL/J mice.
J. Immunol.
152:908-918[Abstract].
|
| 22.
|
Grewal, I. S., and R. A. Flavell.
1996.
The role of CD40 ligand in costimulation and T-cell activation.
Immunol. Rev.
153:85-106[CrossRef][Medline].
|
| 23.
|
Hampson, D. R., and S. E. Poduslo.
1986.
Purification of proteolipid protein and production of specific antiserum.
J. Neuroimmunol.
11:117-129[CrossRef][Medline].
|
| 24.
|
Harry, G. J.,
M. Billingsley,
A. Bruinink,
I. L. Campbell,
W. Classen,
D. C. Dorman,
C. Galli,
D. Ray,
R. A. Smith, and H. A. Tilson.
1998.
In vitro techniques for the assessment of neurotoxicity.
Environ. Health Perspect.
106(Suppl. 1):131-158.
|
| 25.
|
Hoffmann, J. A.,
F. C. Kafatos,
C. A. Janeway, and R. A. Ezekowitz.
1999.
Phylogenetic perspectives in innate immunity.
Science
284:1313-1318[Abstract/Free Full Text].
|
| 26.
|
June, C. H.,
J. A. Bluestone,
L. M. Nadler, and C. B. Thompson.
1994.
The B7 and CD28 receptor families.
Immunol. Today
15:321-331[CrossRef][Medline].
|
| 27.
|
Kanakaraj, P.,
K. Ngo,
Y. Wu,
A. Angulo,
P. Ghazal,
C. A. Harris,
J. J. Siekierka,
P. A. Peterson, and W. P. Fung-Leung.
1999.
Defective interleukin (IL)-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice.
J. Exp. Med.
189:1129-1138[Abstract/Free Full Text].
|
| 28.
|
Karpus, W. J.,
N. W. Lukacs,
B. L. McRae,
R. M. Streiter,
S. L. Kunkel, and S. D. Miller.
1995.
An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis.
J. Immunol.
155:5003-5010[Abstract].
|
| 29.
|
Karpus, W. J.,
J. G. Pope,
J. D. Peterson,
M. C. Dal Canto, and S. D. Miller.
1995.
Inhibition of Theiler's virus-mediated demyelination by peripheral immune tolerance induction.
J. Immunol.
155:947-957[Abstract].
|
| 30.
|
Katz-Levy, Y.,
K. L. Neville,
A. M. Girvin,
C. L. Vanderlugt,
J. G. Pope,
L. J. Tan, and S. D. Miller.
1999.
Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice.
J. Clin. Investig.
104:599-610[Medline].
|
| 31.
|
Katz-Levy, Y.,
K. L. Neville,
J. Padilla,
S. M. Rahbe,
W. S. Begolka,
A. M. Girvin,
J. K. Olson,
C. L. Vanderlugt, and S. D. Miller.
2000.
Temporal development of autoreactive Th1 responses and endogenous antigen presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice.
J. Immunol.
165:5304-5314[Abstract/Free Full Text].
|
| 32.
|
Kreutzberg, G. W.
1996.
Microglia: a sensor for pathological events in the CNS.
Trends Neurosci.
19:312-318[CrossRef][Medline].
|
| 33.
|
Kurtzke, J. F.
1993.
Epidemiologic evidence for multiple sclerosis as an infection.
Clin. Microbiol. Rev.
6:382-427[Abstract/Free Full Text].
|
| 34.
|
Levy, M.,
C. Aubert, and M. Brahic.
1992.
Theiler's virus replication in brain macrophages cultured in vitro.
J. Virol.
66:3188-3193[Abstract/Free Full Text].
|
| 35.
|
Li, H.,
M. L. Cuzner, and J. Newcombe.
1996.
Microglia-derived macrophages in early multiple sclerosis plaques.
Neuropathol. Appl. Neurobiol.
22:207-215[CrossRef][Medline].
|
| 36.
|
Ling, E. A.,
D. Penney, and C. P. Leblond.
1980.
Use of carbon labeling to demonstrate the role of blood monocytes as precursors of the `ameboid cells' present in the corpus callosum of postnatal rats.
J. Comp. Neurol.
193:631-657[CrossRef][Medline].
|
| 37.
|
Lipton, H. L., and M. C. Dal Canto.
1979.
Susceptibility of inbred mice to chronic central nervous system infection by Theiler's murine encephalomyelitis virus.
Infect. Immun.
26:369-374[Abstract/Free Full Text].
|
| 38.
|
Lipton, H. L., and A. Friedmann.
1980.
Purification of Theiler's murine encephalomyelitis virus and analysis of the structural virion polypeptides: correlation of the polypeptide profile with virulence.
J. Virol.
33:1165-1172[Abstract/Free Full Text].
|
| 39.
|
Lipton, H. L.,
J. Kratochvil,
P. Sethi, and M. C. Dal Canto.
1984.
Theiler's virus antigen detected in mouse spinal cord 2 1/2 years after infection.
Neurology
34:1117-1119[Abstract/Free Full Text].
|
| 40.
|
Lipton, H. L.,
G. Twaddle, and M. L. Jelachich.
1995.
The predominant virus antigen burden is present in macrophages in Theiler's murine encephalomyelitis virus-induced demyelinating disease.
J. Virol.
69:2525-2533[Abstract].
|
| 41.
|
Malik, N.,
B. W. Greenfield,
A. F. Wahl, and P. A. Kiener.
1996.
Activation of human monocytes through CD40 induces matrix metalloproteinases.
J. Immunol.
156:3952-3960[Abstract].
|
| 42.
|
Medzhitov, R., and C. A. Janeway, Jr.
1997.
Innate immunity: impact on the adaptive immune response.
Curr. Opin. Immunol.
9:4-9[CrossRef][Medline].
|
| 43.
|
Medzhitov, R., and C. A. Janeway, Jr.
1997.
Innate immunity: the virtues of a nonclonal system of recognition.
Cell
91:295-298[CrossRef][Medline].
|
| 44.
|
Miller, S. D., and S. J. Gerety.
1990.
Immunologic aspects of Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease.
Semin. Virol.
1:263-272.
|
| 45.
|
Miller, S. D.,
S. J. Gerety,
M. K. Kennedy,
J. D. Peterson,
J. L. Trotter,
V. K. Tuohy,
C. Waltenbaugh,
M. C. Dal Canto, and H. L. Lipton.
1990.
Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. III. Failure of neuroantigen-specific immune tolerance to affect the clinical course of demyelination.
J. Neuroimmunol.
26:9-23[CrossRef][Medline].
|
| 46.
|
Miller, S. D., and W. J. Karpus.
1994.
The immunopathogenesis and regulation of T-cell mediated demyelinating diseases.
Immunol. Today
15:356-361[CrossRef][Medline].
|
| 47.
|
Miller, S. D.,
C. L. Vanderlugt,
W. S. Begolka,
W. Pao,
R. L. Yauch,
K. L. Neville,
Y. Katz-Levy,
A. Carrizosa, and B. S. Kim.
1997.
Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading.
Nat. Med.
3:1133-1136[CrossRef][Medline].
|
| 48.
|
Nikcevich, K. M.,
K. B. Gordon,
L. Tan,
S. D. Hurst,
J. F. Kroepfl,
M. Gardinier,
T. A. Barrett, and S. D. Miller.
1997.
Interferon-gamma activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells.
J. Immunol.
158:614-621[Abstract].
|
| 49.
|
O'Garra, A.,
L. Steinman, and K. Gijbels.
1997.
CD4+ T-cell subsets in autoimmunity.
Curr. Opin. Immunol.
9:872-883[CrossRef][Medline].
|
| 50.
|
Ota, K.,
M. Matsui,
E. L. Milford,
G. A. Mackin,
H. L. Weiner, and D. A. Hafler.
1990.
T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis.
Nature
346:183-187[CrossRef][Medline].
|
| 51.
|
Perry, V. H.,
P. B. Andersson, and S. Gordon.
1993.
Macrophages and inflammation in the central nervous system.
Trends Neurosci.
16:268-273[CrossRef][Medline].
|
| 52.
|
Pope, J. G.,
C. L. Vanderlugt,
H. L. Lipton,
S. M. Rahbe, and S. D. Miller.
1998.
Characterization of and functional antigen presentation by central nervous system mononuclear cells from mice infected with Theiler's murine encephalomyelitis virus.
J. Virol.
72:7762-7771[Abstract/Free Full Text].
|
| 53.
|
Reiss, C. S., and T. Komatsu.
1998.
Does nitric oxide play a critical role in viral infections?
J. Virol.
72:4547-4551[Free Full Text].
|
| 54.
|
Sedgwick, J. D.,
D. S. Riminton,
J. G. Cyster, and H. Korner.
2000.
Tumor necrosis factor: a master-regulator of leukocyte movement.
Immunol. Today
21:110-113[CrossRef][Medline].
|
| 55.
|
Selmaj, K., and C. S. Raine.
1988.
Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro.
Ann. Neurol.
23:339-346[CrossRef][Medline].
|
| 56.
|
Sen, G. C., and P. Lengyel.
1992.
The interferon system. A bird's eye view of its biochemistry.
J. Biol. Chem.
267:5017-5020[Free Full Text].
|
| 57.
|
Shimizu, Y.,
W. Newman,
Y. Tanaka, and S. Shaw.
1992.
Lymphocyte interactions with endothelial cells.
Immunol. Today
13:106-112[CrossRef][Medline].
|
| 58.
|
Shrikant, P., and E. N. Benveniste.
1996.
The central nervous system as an immunocompetent organ: role of glial cells in antigen presentation.
J. Immunol.
157:1819-1822[Abstract].
|
| 59.
|
Streit, W.
1995.
Microglia, p. 85-96.
In
H. Kettenmann, and B. R. Ransom (ed.), Neuroglia. Oxford University Press, Oxford, England.
|
| 60.
|
Tan, L. J.,
K. B. Gordon,
J. P. Mueller,
L. A. Matis, and S. D. Miller.
1998.
Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes.
J. Immunol.
160:4271-4279[Abstract/Free Full Text].
|
| 61.
|
Tian, L.,
R. J. Noelle, and D. A. Lawrence.
1995.
Activated T cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1.
Eur. J. Immunol.
25:306-309[Medline].
|
| 62.
|
Traugott, U.,
E. L. Reinherz, and C. S. Raine.
1983.
Multiple sclerosis: distribution of T cell subsets and Ia- positive macrophages in lesions of different ages.
J. Neuroimmunol.
4:201-221[CrossRef][Medline].
|
| 63.
|
van der Veen, R. C.,
D. R. Hinton,
F. Incardonna, and F. M. Hofman.
1997.
Extensive peroxynitrite activity during progressive stages of central nervous system inflammation.
J. Neuroimmunol.
77:1-7[CrossRef][Medline].
|
| 64.
|
van Snick, J.
1990.
Interleukin-6: an overview.
Annu. Rev. Immunol.
8:253-278[Medline].
|
| 65.
|
Walker, W. S.,
J. Gatewood,
E. Olivas,
D. Askew, and C. E. Havenith.
1995.
Mouse microglial cell lines differing in constitutive and interferon-gamma-inducible antigen-presenting activities for naive and memory CD4+ and CD8+ T cells.
J. Neuroimmunol.
63:163-174[CrossRef][Medline].
|
| 66.
|
Weissenbock, H.,
M. Hornig,
W. F. Hickey, and W. I. Lipkin.
2000.
Microglial activation and neuronal apoptosis in Bornavirus infected neonatal Lewis rats.
Brain Pathol.
10:260-272[Medline].
|
| 67.
|
Wekerle, H.
1993.
Experimental autoimmune encephalomyelitis as a model of immune-mediated CNS disease.
Curr. Opin. Neurobiol.
3:779-784[CrossRef][Medline].
|
| 68.
|
Xiao, B. G., and H. Link.
1999.
Is there a balance between microglia and astrocytes in regulating Th1/Th2-cell responses and neuropathologies?
Immunol. Today
20:477-479[CrossRef][Medline].
|
| 69.
|
Yauch, R. L.,
K. Kerekes,
K. Saujani, and B. S. Kim.
1995.
Identification of a major T-cell epitope within VP3(24-37) of Theiler's virus in demyelination-susceptible SJL/J mice.
J. Virol.
69:7315-7318 |